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Presentation of case
Keywords Chronic diarrhea · Sprue · Subtotal villous 
atrophy · Olmesartan · Drug-associated enteropathy · 
Adverse drug effect · Delayed hypersensitivity reaction · 
Hypokalemia
Dr. D. Schiller: After two previous hospitalizations, an 82-year-
old woman was readmitted with chronic diarrhea of 
8-month duration and weight loss of 20 kg. This had left her 
so weak that she could no longer look after herself.
The watery diarrhea had started 8 months before and 
sometimes was worse at night. She had up to 12 bowel 
movements per day without abdominal pain and had lost 
her appetite. Duodenal biopsies revealed subtotal villous 
atrophy with crypt hyperplasia and increased intraepi-
thelial lymphocytes (40 per 100 epithelial cells). Tissue 
transglutaminase antibodies and serum anti-endomysial 
antibodies were negative. Serum immunoglobulins (IgG, 
IgA, and IgM), thyroid stimulating hormone (TSH), dif-
ferential blood count, anti-HIV antibody, ova and para-
sites in stool (three times), colonoscopy with multiple 
biopsies, capsule endoscopy of the small bowel, and 
abdominal computerized tomography were all nega-
tive or normal. Biopsies from ileoscopy showed changes 
similar to the proximal small bowel. Human leukocyte 
antigen (HLA)-DQ2 (positive) and DQ8 (negative) geno-
typing were compatible with celiac disease. Intestinal 
lymphocytes showed no T-cell receptor rearrangement. 
A strict gluten-free diet did not ameliorate the diarrhea 
but it improved slightly under budesonide medication. 
Finally, during this third hospitalization, a diagnosis of 
“refractory sero-negative celiac disease” was established.
Her medical history was positive for paroxysmal atrial 
fibrillation, hypertension, hypothyroidism following 
autoimmune thyreoiditis and chronic depression. Her 
history was negative for previous gastrointestinal com-
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plaints, foreign travel, and fever. Her family history was 
non-revealing.
Her medications included budesonide, amiodarone, 
olmesartan, amlodipine, thyroid replacement therapy 
(levothyroxine, liothyronine), trazodone, risperidone, 
and lorazepam.
On admission the patient was afebrile, body weight 
was 45  kg, height 162  cm; she was in poor general and 
nutritional condition (body mass index: 17.1  kg/m2). 
Blood pressure was 135/90  mmHg, bowel sounds were 
hyperactive. She appeared slightly dehydrated. Abnor-
mal laboratory results included serum potassium 
3.3 mmol/l (normal: 3.6–4.8 mmol/l), C-reactive protein 
(CRP) 1.5  mg/l (normal: < 0.5  mg/l), and hemoglobin 
11.1 g/dl (normal: 13.0–17.5 g/dl). All other results were 
negative or normal including urine dip stick, fecal occult 
blood, and calprotectin.
A diagnostic insight allowed an explanation for the 
severe diarrhea.
Dr. C. Lackner: Histological examination of the duodenal 
biopsies mentioned in the protocol revealed subtotal vil-
lous atrophy, chronic inflammation of the lamina propria 
and increased intraepithelial lymphocytes (approximately 
40 per 100 epithelial cells), reactive and degenerative epi-
thelial changes as well as crypt hyperplasia (Fig. 1). These 
histopathological features are not very specific and can be 
found with celiac disease, Crohn’s disease, enteric infection, 
collagenous sprue, tropical sprue, bacterial overgrowth, 
common variable immunodeficiency, autoimmune enter-
opathy, and hematological malignancies, and have also 
been reported as side effects of immunosuppressant drugs 
[1, 2]. In this case, small bowel histology is compatible with 
a wide spectrum of diseases.
Differential diagnosis
Dr. H. Wenzl: This is a case of chronic diarrhea. When 
a patient presents with this condition, a detailed medi-
cal history is pivotal for establishing the correct diagno-
sis. The patient under discussion is an elderly woman 
who had been suffering from chronic watery diarrhea 
for 8 months. She reported up to 12 bowel movements 
in 24 h, even at night. This important finding suggests 
an organic rather than functional cause for her chronic 
diarrhea [3]. Osmotic diarrhea can also be excluded in 
cases with noctural diarrhea because osmotic diarrhea 
always follows shortly after meals, so that it usually sub-
sides during the night. Abdominal pain would be typical 
for inflammatory bowel diseases such as Crohn’s disease, 
irritable bowel syndrome or ischemic colitis but was not 
present here. The negative hemoccult and calprotectin 
speak against inflammatory mucosal diseases, as did the 
normal colon biopsies. A weight loss of 20 kg is remark-
able and suggests severe bowel dysfunction including 
malabsorption, chronic inflammation and neoplasia, 
and demands extensive morphological examination. The 
patient underwent a pan-endoscopy including esoph-
ago-gastro-duodenal endoscopy, ileocolonoscopy with 
multiple biopsies, and capsule endoscopy of the small 
bowel. The protocol does not describe the macroscopic 
appearance of the duodenum and ileum, but histologi-
cal assessment documented subtotal villous atrophy, 
chronic inflammation, and crypt hyperplasia suggest-
ing celiac disease. In 20–25 % of patients, celiac disease 
first manifests itself at the age of 60 years or older [4], so 
based on histology alone this diagnosis could indeed 
be made for this 82-year-old patient. Tests for celiac 
disease with antibodies to tissue transglutaminase and 
endomysium were, however, negative. Both parameters 
have a high sensitivity and specificity for celiac disease 
[5]. Serum IgA levels were normal. Her HLA-type was 
DQ2 positive and DQ8 negative. In Europe, 85–90 % 
of patients with celiac disease are HLA-DQ2 positive 
and 10–15 % are HLA-DQ8 positive [6]; however, up 
to 30 % of the general population is also HLA-DQ2 or 
DQ8 positive but without the disease [7]. Celiac dis-
ease is defined as immune-mediated enteropathy with 
a strong genetic predisposition, which improves upon 
dietary exclusion of gluten [8]. Gluten is digested by 
luminal and brush-border enzymes into amino acids 
and polypeptides. The gliadin peptides induce immu-
nological changes in the epithelium and in the lamina 
propria. Gliadin damages epithelial cells, leading to 
increased expression of interleukin-15, which in turn 
activates intraepithelial lymphocytes. These lympho-
cytes are cytotoxic and damage enterocytes expressing 
the surface protein MIC-A (major-histocompatibility-
complex class I chain-related A). During infections or 
as the result of permeability changes, gliadin can enter 
the lamina propria, where it is deamidated by tissue 
transglutaminase, allowing interaction with HLA-DQ2 
or HLA-DQ8 on the surface of antigen-presenting cells. 
Presentation of gliadin to gliadin-reactive CD4 + T cells 
through a T cell receptor thus results in production 
of cytokines that cause tissue damage, subsequently 
leading to villous atrophy, crypt hyperplasia, and acti-
vation and expansion of B cells that produce antibod-
ies [7].
Fig. 1 Duodenal biopsy showing subtotal villous atrophy and 
crypt hyerplasia (H&E, ×100)
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[15]. Other diseases with small intestinal villous atrophy 
that merit consideration are giardiasis, HIV enteropathy, 
tuberculosis, radiation enteritis, Zollinger–Ellison syn-
drome, Whipple’s disease, intestinal lymphoma, food 
intolerances [16], alpha chain disease, graft-versus-host 
disease, hypogammaglobulinemia, severe malnutrition 
[5], and certain medications [17]. The medical history 
shows no evidence for most of these diseases; there are 
no further specific histopathological findings and there 
is no other serological abnormality. This leads us to limit 
the differential diagnosis to non-responsive sprue, post-
gastroenteritis syndrome, small intestinal bacterial over-
growth, autoimmune enteropathy, and Zollinger–Ellison 
syndrome. A strict gluten-free diet over a longer period 
of time would show whether the patient suffers from 
truly non-responsive sprue. A post-gastroenteritis syn-
drome would be self-limiting (“watch and wait”); small 
intestinal bacterial overgrowth could be sought with an 
H2-breath test and analysis of duodenal aspirate, and 
treated with oral antibiotics; an autoimmune enteropa-
thy could be diagnosed by an experienced gastrointes-
tinal pathologist’s review of the biopsies and enterocyte 
antibodies; and in case of Zollinger–Ellison syndrome, 
serum gastrin would be increased, usually together 
with a tumor in the pancreas or duodenal wall. Actually, 
none of these diagnoses really seems to be likely in our 
patient. According to our list of potential causes for NCE, 
only a careful review of the patient’s medication is left, 
because some drugs might have adverse gastrointestinal 
effects (Table  1). Of the eight different medications our 
patient took, five document diarrhea as an adverse effect. 
Diarrhea is indeed a ommon drug-associated adverse 
Treatment for celiac disease is a gluten-free diet, 
which usually results in recovery of the mucosa and 
return to normal health. Our patient, however, did 
not respond to this diet, as is the case with 0.3–30 % of 
patients with celiac disease, who are subsequently diag-
nosed as refactory celiac disease (RCD) [9–12]. There are 
two types of RCD: type 1 shows a normal intraepithelial 
lymphocyte population, whereas type 2 displays a pre-
dominantly aberrant intraepithelial lymphocyte pheno-
type [13]. Taking all these findings together, our patient 
could have RCD type I, but I think this diagnosis has to be 
questioned because she is an elderly woman who might 
have had trouble following a strict gluten-free diet. More-
over, we speak of non-responsive sprue if patients do not 
respond to strict gluten-free diet for 6–12 months and of 
RCD if patients do not respond to strict gluten-free diet 
for ≥ 12 months and other causes of villous atrophy have 
been excluded [14]. Based on the information given in 
the protocol, our patient had, however, not been on a glu-
ten-free diet long enough and as already mentioned, the 
elderly patient may not have been able to comply with it. 
Still, the negative celiac serology and the supposed non-
response to a gluten-free diet urge us to consider other 
non-celiac enteropathies (NCE) presenting with villous 
atrophy. The diagnostic algorithm for small intestinal 
villous atrophy (Fig. 2) indicates that other etiologies of 
NCE have to be considered here [15]. These include com-
mon variable immunodeficiency, food allergies, tropical 
sprue, post viral enteropathy, eosinophilic gastroenteri-
tis, peptic duodenitis, autoimmune enteropathy, small 
intestinal bacterial overgrowth, immune-mediated 
enteropathy, Crohn’s disease, and collagenous sprue 





Fig. 2 Diagnostic algorithm for small intestinal villous atrophy 
[15]. The diagnostic path followed with our patient is marked 
in blue. When the result (“Manage as presumptive CD”) did 
not satisfy the clinicians they returned to square “Review pa-
thology, consider NCE” (left upper corner). Only when at this 
point additional other differential diagnoses were considered 
(see text), did her physicians arrive at the right diagnosis. 
tTG tissue transglutaminase, Ig immunoglobulin, NCE non- 
celiac enteropathy, DGP deamidated gliadin peptide, 
HLA human leukocyte antigen, CVID common variable im-
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Discussion of diagnosis
Dr. G. J. Krejs: Dr. Schiller was the attending physician 
who cared for the patient and will describe further details 
of the patient’s course.
Dr. D. Schiller: Arriving at a diagnosis in this case was 
challenging. Within a short period of time we observed 
a second patient with the same clinical picture and 
enteropathy. When we contacted Dr. Nadine Cerf-Ben-
sussan at the Laboratory for Intestinal Immunity in Paris 
requesting determination of anti-enterocyte antibodies 
(which subsequently turned out to be negative in both 
patients), we were asked the decisive question of whether 
our patients were taking olmesartan. Discontinuation of 
the medication resolved the diarrhea within several days 
and both patients began to gain weight. Although there 
are many potential causes for NCE, gastroenterologists 
should be aware that olmesartan can cause enteropa-
thy. Olmesartan has now been reported to be associated 
with sprue-like enteropathy [18, 20, 23, 25]. Our first two 
cases of olmesartan-associated enteropathy are currently 
being published as a clinical vignette in the journal “Gut” 
[28].
Meanwhile, a third patient presented with olmesar-
tan-associated enteropathy at our hospital in Linz. All 
patients received a primary diagnosis of non-respon-
sive/refractory celiac disease or unexplained sprue. 
Typical symptoms such as diarrhea and massive weight 
loss (10‒20  kg) always occurred after a longer period of 
olmesartan intake. In all patients, clinical response was 
rapid after olmesartan was discontinued and histological 
recovery was confirmed in all three patients by follow-
up biopsy within 2 months. Since our patients’ recover-
ies were so striking and they had already been suffering 
for so long, we did not want to rechallenge them with 
olmesartan to reproduce the chronic diarrhea and vil-
lous atrophy.
Dr. G. J. Krejs: Dr. Lackner, our pathologist, will show and 
explain the follow-up biopsy after the patient had been 
off olmesartan for 2 months.
Dr. C. Lackner: Follow-up duodenal biopsy showed com-
plete mucosal recovery. The initially described histo-
pathological features including villous atrophy, chronic 
inflammation, reactive and degenerative epithelial 
alterations, and crypt hyperplasia were not present 
in the specimen after discontinuation of olmesartan. 
Villus:crypt ratio was within normal range (Fig. 3).
Dr. G. J. Krejs: Currently, an association between olmes-
artan intake and development of sprue-like enteropa-
thy, mainly characterized by diarrhea, weight loss and 
variable degrees of duodenal mucosal damage is being 
noted by gastroenterologists and some 90 cases have 
been documented worldwide. Dr. Donnerer is a clinical 
pharmacologist and will explain possible mechanisms of 
olmesartan-associated enteropathy.
event, and the underlying mechanisms are often unclear 
[18]. Diarrhea due to drug-induced enteropathy has 
been reported for medications such as mycophenolate 
mofetil [19, 20], methotrexate [21, 22], azathioprine [23] 
and most recently olmesartan. Among the medications 
taken by our patient, only one, olmesartan, is associated 
with villous atrophy resulting in sprue-like enteropathy. 
Olmesartan is an angiotensin II receptor antagonist that 
has been commonly prescribed for treatment of hyper-
tension since 2002 [24]. The association between sprue-
like enteropathy and olmesartan was first reported in 
2012 [18]. Clinical features of this enteropathy include 
gastrointestinal symptoms such as diarrhea, weight 
loss and steatorrhea, negative IgA tissue transglutamin-
ase antibodies (or endomysial-antibodies), evidence of 
enteropathy (villous atrophy) with or without collagen 
deposition or intraepithelial lymphocytes, lack of clini-
cal response to a gluten-free diet, and exclusion of other 
causes of enteropathy [18]. Since our patient took olmes-
artan and presented with unexplained diarrhea, I suggest 
that she suffers from olmesartan-associated sprue-like 
enteropathy. Symptoms typically occur after olmesar-
tan has been taken for months or years; this enteropa-
thy can affect almost the entire gut [18], and can present 
a spectrum of histological damage (from normal villi to 
partial or total villous atrophy with variable degrees of 
mucosal inflammation) [25]. The mechanisms underly-
ing olmesartan-associated enteropathy are still unclear. 
Interestingly, approximately 70 % of patients with olmes-
artan-associated enteropathy are HLA-DQ2 or HLA-DQ8 
positive, which is a higher prevalence than expected in 
the general population (25–30 %) [26, 27]. This suggests 
that the presence of HLA-DQ2 or HLA-DQ8 may increase 
the risk for immune-mediated mucosal damage in these 
patients, but further studies must clarify this. Withdrawal 
of olmesartan intake usually results in rapid clinical 
and histological improvement of the enteropathy. With-
drawal of olmesartan is thus indicated for our patient.
Dr. H. Wenzl’s diagnosis
Olmesartan-associated sprue-like enteropathy.
Table 1 Patient’s medication and documented adverse 
gastrointestinal effects (Summary of Product Characteris-
tics)
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binds to two forms of receptors with different properties. 
AT1 receptor is expressed throughout the gastrointestinal 
tract; it activates growth-promoting factors and mediates 
major effects of angiotensin II. AT2 is mainly found in 
the duodenum and jejunum, and induces effects oppos-
ing those of AT1 [35, 36]. Recent studies have shown that 
binding of angiotensin II to AT2 promotes apoptosis of 
enterocytes by up-regulation of pro-apoptotic protein 
associated with a down-regulation of anti-apoptotic 
protein [37]. Moreover, in rat smooth muscle cells, drug-
induced AT1 receptor blocking has been found to cause 
translocation of AT2 receptors from cytosol to external 
membrane, which may favor binding of angiotensin II to 
AT2 [38]. Olmesartan has a high affinity for AT1 recep-
tors; in the case of drug-mediated saturation of these 
receptors, angiotensin II could increasingly bind to AT2 
receptors and thus induce apoptotic effects, leading to 
villous atrophy without inflammation and increase in 
intraepithelial lymphocytes [1]. This mechanism is, how-
ever, still controversial because such effects have not 
been described for other angiotensin II receptor antago-
nists, which would be expected since interaction with the 
AT1 receptor is the basic therapeutic mechanism under-
lying this group of antihypertensives.
At present, olmesartan-associated sprue-like enter-
opathy may be considered an adverse effect. Since the 
underlying mechanisms are still unclear, more stud-
ies involving rechallenge with either olmesartan or 
placebo are needed. At this time a cause-effect rela-
tionship should be classified as only probable [39]. A 
similar enteropathy has been reported after telmisar-
tan and irbesartan, and it is open to question whether 
these changes could be a class effect of sartans [40–42]. 
In relation to the worldwide use of olmesartan for anti-
hypertensive therapy, olmesartan-associated sprue-like 
enteropathy occurs only rarely. However, doctors should 
be aware of this association when a patient under therapy 
with olmesartan presents with unexplained chronic diar-
rhea. The regulatory authorities have recently ordered 
that a special warning regarding sprue-like enteropathy 
be included in the SPC (Summary of Product Charac-
teristics) of olmesartan medoxomil; however, since this 
side effect is so rare, no suggestion has been made to take 
olmesatran off the market.
One other comment on the medication of this patient 
is that she received three drugs (trazodone, risperidone, 
and lorazepam) that target the central nervous system 
(CNS). The weakness mentioned at the beginning of the 
protocol was probably due to her dramatic weight loss 
and possibly to hypokalemia, but the CNS effects of her 
medication should also be considered and the neces-
sity for all the medication she is receiving should be 
reevaluated.
Dr. G. J. Krejs: Dr. Wenzl, as a diarrhea expert, what do you 
say about the hypokalemia albeit mild in this patient? 
When does chronic diarrhea lead to hypokalemia? And 
what is your final comment on this case?
Dr. J. Donnerer: Generally, many drugs can exert adverse 
effects involving different organ systems and tissues. 
When medication is administered orally, the gastroin-
testinal tract is often affected by adverse events for the 
simple reason of being exposed to high drug concen-
trations. Olmesartan is an orally administered prodrug 
(olmesartan medoxomil) that is rapidly metabolized to 
the active component (olmesartan) by esterases in the 
gastrointestinal mucosa, portal blood and liver [29]. The 
mechanisms involved in olmesartan-associated enter-
opathy are still not fully understood.
A delayed drug hypersensitivity reaction may be the 
underlying mechanism leading to enteropathy under 
olmesartan therapy. Some medications can provoke 
allergic type B reactions if the pharmaceutical substance 
acts as a hapten and combines with a body’s own protein 
to form an antigen, thus inducing allergization. Gener-
ally, there are four different types of hypersensitivity 
reactions which can result in drug-induced allergization: 
type I (anaphylaxis), type II (cytotoxic effects), type III 
(immune-complex hypersensitivity), and type IV (T lym-
phocyte-mediated reactions, delayed hypersensitivity). 
Considering the long period of months or years between 
onset of olmesartan therapy and appearance of villous 
atrophy, it is suggested that a delayed type IV hypersensi-
tivity reaction may cause the sprue-like enteropathy.
Some angiotensin (AT) receptor blockers are sug-
gested to have inhibitory effects on transforming growth 
factor-beta 1 [30, 31], which is pivotal for maintaining 
gut immune homeostasis [32, 33]. Duodenal biopsies 
from patients under olmesartan therapy show a signifi-
cant increase in the number of CD8 + cells, assuming that 
olmesartan-associated sprue-like enteropathy may be 
due to either an expansion of cytotoxic CD8 + T cells, or a 
dysfunctional intestinal regulatory mechanism that nor-
mally suppresses CD8 + T cell activity [34].
Another possible mechanism underlying villous atro-
phy in olmesartan-associated enteropathy might be a 
pro-apoptotic effect on intestinal epithelial cells medi-
ated by angiotensin II. In the human gut, angiotensin II 
Fig. 3 Normal villus and crypt architecture in duodenal biopsy 
3 months after discontinuation of olmesartan (H&E, ×200)
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Dr. H. Wenzl: Hypokalemia is always a sign of chronic large-
volume diarrhea. The transport mechanisms in the colon 
try to conserve sodium but potassium has to go into the 
lumen in exchange. With a normal stool, 5 meq of potas-
sium are discharged every day; with a liter of watery stool 
there is a potassium loss of 50  meq/l per day [43–45]. 
This slowly depletes total body potassium (50  meq/kg) 
and ultimately results in hypokalemia. Hypokalemia is 
prominent in pancreatic cholera or Verner–Morrison 
syndrome, where it is part of the name of the condition 
(WDHH syndrome or watery diarrhea hypochlorhydria 
hypokalemia syndrome) [46]. It is also observed with 
chronic laxative abuse. That the patient had slight hypo-
kalemia indicates long-standing large-volume diarrhea.
This case is very interesting and emphasizes the diag-
nostic dilemma when patients with villous atrophy have 
either negative celiac serology or do not respond to a 
gluten-free diet. Under these circumstances, a broad 
spectrum of other etiologies for enteropathy has to be 
considered. A side effect of medication as a cause, espe-
cially when olmesartan is involved, should be part of the 
initial differential diagnosis of such unexplained enter-




The authors express their sincere gratitude to Eugenia 
Lamont for language editing of the manuscript.
Conflict of interest 
All authors declare that there are no conflicts of interest.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution License which permits any use, 
distribution, and reproduction in any medium, provided the 
original author(s) and the source are credited. 
References
 1. Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, 
Cammarota G. Systematic review: sprue-like enteropa-
thy associated with olmesartan. Aliment Pharmacol Ther. 
2014;40(1):16–23.
 2. Greenson JK. The biopsy pathology of non-coeliac enter-
opathy. Histopathology. 2015;66(1):29–36.
 3. Krejs GJ. Cecil textbook of medicine. 19th ed. Philadelphia: 
WB Saunders; 1992. pp. 680–7. (Chapter: Diarrhea).
 4. Beaumont DM, Mian MS. Coeliac disease in old age: “a 
catch in the rye”. Age Ageing. 1998;27(4):535–8.
 5. Feldmann M, Friedmann LS, Brandt LJ, editors. Sleisenger 
and Fordtran’s gastrointestinal and liver disease. 10th ed. 
Philadelphia: Elsevier Sounders; 2015.
 6. Megiorni F, Mora B, Bonamico M, Berbato M, Nenna R, 
Maiella G, Lulli P, Mazzilli MC. HLA-DQ and risk gradient 
for celiac disease. Hum Immunol. 2009;70(1):55–9.
Clinical-Pathological Conference
980  Clinical-Pathological Conference Series from the Medical University of Graz 1 3
37. Sun L, Wang W, Xiao W, Liang H, Yang Y, Yang H. Angio-
tensin II induces apoptosis in intestinal epithelial cells 
through the AT2 receptor, GATA-6 and the Bax pathway. 
Biochem Biophys Res Commun. 2012;424(4):663–8.
38. De Godoy MA, Rattan S. Translocation of AT1- and AT2-
receptors by higher concentrations of angiotensin II in the 
smooth muscle cells of rat internal anal sphincter. J Phar-
macol Exp Ther. 2006;319(3):1088–95.
39. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts 
EA, Janecek E, Domecq C, Greenblatt DJ. A method for 
estimating the probability of adverse drug reactions. Clin 
Pharmacol Ther. 1981;30(2):239–45.
40. Cyrano J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova 
M. Telmisartan-associated enteropathy—is there any class 
effect? Aliment Pharmacol Ther. 2014;40(5):569–70.
41. Cammarota G, Ianiro G, Bibbo S, Gasbarrini A. Telmisartan 
associated enteropthy—is there any class effect? Aliment 
Pharmacol Ther. 2014;40(5):570.
42. Marietta EV, Cartee A, Rishi A, Murray JA. Drug-induced 
enteropathy. Dig Dis. 2015;33(2):215–20.
43. Wenzl HH, Fine KD, Santa Ana CA, Porter JL, Fordtran JS. 
Effect of fludrocortisone and spironolactone on sodium 
and potassium losses in secretory diarrhea. Dig Dis Sci. 
1997;42(1):119–28.
44. Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of 
potassium absorption and secretion by the human intes-
tine. Gastroenterology. 1994;107(2):548–71.
45. Giebisch G. Challenges to potassium metabolism: internal 
distribution and external balance. Wien Klin Wochenschr. 
2004;116(11–12):353–66.
46. Krejs GJ. VIPoma syndrome. Am J Med. 1987;82(Suppl. 513): 
37–48.
47. Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira 
PJ, Green PH, Hadjivassiliou M, Holdoway A, van Heel 
DA, Kaukinen K, Leffler DA, Leonard JN, Lundin KE, 
McGough N, Davidson M, Murray JA, Swift GL, Walker 
MM, Zingone F, Sanders DS, BSG Coeliac Disease Guide-
lines Development Group, British Society of Gastroenterol-
ogy. Diagnosis and management of adult coeliac disease: 
guidelines from the British Society of Gastroenterology. 
Gut. 2014;63(8):1210–1228.
25. Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, 
Skinazi F, Mesnard B, Chayvialle JA, Savoye G, Druez A, 
Parlier D, Abitbol V, Gompel M, Eoche M, Poncin E, Bobi-
chon R, Colardelle P, Wils P, Salloum H, Peschard S, Zerbib 
F, Méresse B, Cerf-Bensussan N, Malamut G, Carbonnel F. 
Olmesartan-associated enteropathy: results of a national 
survey. Aliment Pharmacol Ther. 2014;40(9):1103–9.
26. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby 
E. Evidence for a primary association of celiac disease to 
a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 
1989;169(1):345–50.
27. Kaukinen K, Partanen J, Mäki M, Collin P. HLA-DQ typ-
ing in the diagnosis of celiac disease. Am J Gastroenterol. 
2002;97(3):695–9.
28. Schiller D, Ziachehabi A, Silye R, Schöfl R. Two coin-
cident cases of easily curable “refractory sprue”. Gut. 
2015;64(11):1773.
29. Scott LJ, McCormack PL. Olmesartan medoxomil: a review 
of its use in the management of hypertension. Drugs. 
2008;68(9):1239–72.
30. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch 
D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, 
Huso DL, McDonnell NB, Van Eyk JE, Dietz HC, GenTAC 
Consortium. Circulating transforming growth factor-beta 
in Marfan syndrome. Circulation. 2009;120(6):526–32.
31. Kagami S, Border WA, Miller DE, Noble NA. Angioten-
sin II stimulates extracellular matrix protein synthesis 
through induction of transforming growth factor-beta 
expression in rat glomerular mesangial cells. J Clin Invest. 
1994;93(6):2431–7.
32. Macdonald TT, Monteleone G. Immunity, inflammation, 
and allergy in the gut. Science. 2005;307(5717):1920–5.
33. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. 
Regulatory T cells and intestinal homeostasis. Immunol 
Rev. 2005;204:184–94.
34. Rubio-Tapia A. Sprue-like enteropathy associated with 
olmesartan—broadening the differential diagnosis of enter-
opathy. Aliment Pharmacol Ther. 2014;40(11–12):1362–3.
35. Fändriks L. The angiotensin II type 2 receptor and the gas-
trointestinal tract. J Renin Angiotensin Aldosterone Syst. 
2010;11(1):43–8.
36. Mavromoustakos T, Agelis G, Durdagi S. AT1 antago-
nists: a patent review (2008–2012). Expert Opin Ther Pat. 
2013;23(11):1483–94.
